ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GS3-007a dry suspension

Its studies are mostly in Dwarfism, Pituitary, led by Changchun GeneScience Pharmaceutical.

Furthest: phase 2, since Nov 13, 20252 company-led studies, 1 open or runningNext primary completion: Nov 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical21 open or runningphase 2since Nov 13, 2025Nov 13, 2025Nov 2030phase 2 · NCT07264595

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2025First studies: 2 phase 2 studiesFirst studyNCT07259564, NCT07264595

Ahead

  1. Nov 2030Primary completion: phase 2 study in Pediatric Growth Hormone DeficiencyNCT07264595

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07264595Pediatric Growth Hormone Deficiency · China2RecruitingNov 203088
NCT07259564Dwarfism, Pituitary · China2TerminatedApr 15, 2026120

How it is read

Names in the registry

  • “GS3-007a dry suspension”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.